Blog

Oct 9, 2024, 15:29

A collaboration between MiNK Therapeutics and Autonomous Therapeutics

MiNK Therapeutics and Autonomous Therapeutics have announced a collaboration aimed at developing innovative therapies for metastatic tumors.

MiNK Therapeutics (MiNK, NASDAQ: INKT) has partnered with Autonomous Therapeutics, Inc. to develop innovative therapies for metastatic tumors.

This collaboration will combine Autonomous’ precision encrypted RNA™ technology with MiNK’s iNKT cell therapies, MiNK-215 and agenT-797, evaluated in advanced models of metastatic solid tumors. The goal is to create therapies that selectively target cancer cells while sparing healthy tissue.

Depending on the results, they plan to launch a Phase 1 clinical trial for patients with treatment-resistant metastatic solid tumors, including microsatellite stable (MSS) colorectal cancers.

MiNK Therapeutics is a clinical-stage biopharmaceutical firm dedicated to the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and other immune-mediated conditions.

The company is progressing a diverse pipeline of both native and next-generation engineered iNKT programs, utilizing a platform that enables scalable and reproducible manufacturing for off-the-shelf solutions. MiNK Therapeutics is based in New York, NY.

Autonomous Therapeutics is pioneering a new class of RNA medicines called encRNA, targeting hard-to-treat conditions in oncology and infectious diseases. The company has developed a proprietary pipeline of over 10 encRNA candidates, including AT313, a cancer-activated RNA prodrug designed to selectively eliminate solid tumor cells.

Autonomous has partnered with prominent organizations such as the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health (NIH), and BLUE KNIGHT™, a collaboration between BARDA and Johnson & Johnson Innovation – JLABS.

MiNK Therapeutics shared about their new collaboration with Autonomous Therapeutics. Read the post on LinkedIn below:

“We are excited to announce a new collaboration with Autonomous Therapeutics.

By combining our iNKT cell platform with their cutting-edge encrypted RNA technology, we aim to develop innovative and potentially transformative therapies for treatment-resistant metastatic cancers. Learn more.”

A collaboration between MiNK Therapeutics and Autonomous Therapeutics